Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C

• Main Authors: Y. F. Liaw, J. D. Jia, H. L.Y. Chan, K. H. Han, T. Tanwandee, W. L. Chuang, D. M. Tan, X. Y. Chen, E. Gane, T. Piratvisuth, L. Chen, Q. Xie, J. J.Y. Sung, C. Wat, C. Bernaards, Y. Cui, P. Marcellin
• Other Authors: Chang Gung University College of Medicine
• Format: Article
• Published: 2018
• Subjects: Medicine
• Online Access: https://repository.li.mahidol.ac.th/handle/123456789/12256
• Institution: Mahidol University

As there is currently a lack of consensus on the most appropriate dose and duration of peginterferon alfa-2a (PEG-IFNα-2a) therapy in hepatitis B e antigen (HBeAg)-positive patients, the efficacy and safety of either 24 or 48 weeks' duration and 90 μg/week or 180 μg/week doses were compared. HB...